NCT06230549Completed
Adaptive Radiotherapy in Patients With Gynecological Tumors
Prospective Randomized Validation of Adaptive Radiotherapy in Patients With Gynecological Tumors and Indication for Radiotherapy
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
Prospective randomized evaluation of adaptive radiotherapy in the definitive radiotherapy of locally advanced gynecologic carcinoma (e.g. cervical carcinoma, endometrial carcinoma, vaginal carcinoma), in the postoperative situation or first series of external beam radiotherapy and in patients in whom radical surgery or HDR brachytherapy as dose boost is not an option.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 30 Dec 2023
- Start date
- Jan 2024
- Primary completion date
- Dec 2025
- Lead sponsor
- University Hospital, Essen
- Diseases
- Cervical cancer
- NCT number
- NCT06230549
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From Jan 2024 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recurrent disease Prior Radiotherapy in pelvic region stage pM1 or cM1
Who the study is looking for
- ECOG 0-1 confirmation by histophatology MR of the pelvis staging
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department for Radiotherapy, University Hospital Essen, National Center for Tumor Diseases (NCT) West Coordinator of this site? Confirm its status | Essen | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.